On Friday, Shares of Marvell Technology Group Ltd. (NASDAQ:MRVL), subtract -0.53% and closed at $13.11 in the last trading session. The last trading range of the stock ranges between $13.03 and $13.18. The company’s Market capitalization is $6.68 Billion with the total Outstanding Shares of 512.04 million. Marvell (MRVL), a world leader in storage, cloud infrastructure, Internet of Things (IoT), connectivity and multimedia semiconductor solutions, recently declared the appointment of Mr. Dave Caron as Corporate Controller and Chief Accounting Officer, effective recently. In this role, Mr. Caron will be responsible for managing all the corporate accounting and financial reporting functions across the organization.
“Dave is an practiced finance and accounting executive with a proven track record in the semiconductor industry,” said Jean Hu, Chief Financial Officer, Marvell Technology Group. “I want to welcome Dave to the team and I look forward to his steady leadership as we return the company to profitable growth.”
Most recently, Mr. Caron was the Corporate Controller and Principal Accounting Officer at Maxim Integrated. In this role, he was responsible for overseeing all facets of accounting counting General Ledger, External/Technical Accounting, Accounts Receivable, Stock Administration, Payroll, Fixed Assets, Credit and Collections, in addition to Accounts Payable. Before Maxim, Mr. Caron held finance leadership positions at Read-Rite Corporation and Ernst & Young.
Curis, Inc. (NASDAQ:CRIS), jumped 11.59% and closed at $3.37 in the last trading session. The last trading range of the stock ranges between $2.97 and $3.42. The company’s Market capitalization is $486.89 million with the total Outstanding Shares of 129.47 million. During the 52-week trading session the minimum price at which share price traded, registered at $1.25 and reached to max level of $3.42. Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers. The company develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for advanced lymphomas and multiple myeloma. It also develops CUDC-427 that has accomplished Phase I clinical trials for advanced solid tumor and lymphomas; CA-170, which is in preclinical stage for the treatment of cancer; CA-4948, which is in preclinical stage for the treatment of hematologic cancers; Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma (BCC); and CUDC-305 drug candidate that has accomplished Phase I clinical trials for the treatment of cancers. The company has partnershipagreement with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and partnershipand license agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge.
On the otherhand Prologis Inc (NYSE:PLD), dropped -0.80% and closed at $49.80 in the last trading session. The last trading range of the stock ranges between $49.64 and $51.08. During the 52-week trading session the minimum price at which share price traded, registered at $35.25 and reached to max level of $54.87. Prologis, Inc. (PLD), the global leader in logistics real estate, will host a webcast and conference call with senior administration to discuss third quarter results, current market conditions and future outlook on Thursday, October 20, 2016 at 9:00 a.m. PT / 12:00 p.m. ET.
To access a live broadcast of the call, please dial +1 (877) 256-7020 (toll-free from the United States and Canada) or +1 (973) 409-9692 (from all other countries) and enter conference code 81585906.